The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Open accessAbstract
BACKGROUND: Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor alpha, is an established treatment for Crohn's disease but not ulcerative colitis. METHODS: Two randomized, double-blind, placebo-controlled studies--the Active Ulcerative Colitis Trials 1 and 2 (ACT 1 and ACT 2, respectively)--evaluated the efficacy of infliximab for induction and maintenance therapy in adults with ulcerative colitis. In each study, 364 patients with moderate-to-severe active ulcerative colitis despite treatment with concurrent medications received placebo or infliximab (5 mg or 10 mg per kilogram of body weight) intravenously at weeks 0, 2, and 6 and then every eight weeks through week 46 (in ACT 1) or week 22 (in ACT 2). Patients were followed for 54 weeks in ACT 1 and 30 weeks in ACT 2. RESULTS: In ACT 1, 69 percent of patients who received 5 mg of infliximab and 61 percent of those who received 10 mg had a clinical response at week 8, as compared with 37 percent of those who received placebo (P<0.001 for both comparisons with placebo). A response was defined as a decrease in the Mayo score of at least 3 points and at least 30 percent, with an accompanying decrease in the subscore for rectal bleeding of at least 1 point or an absolute rectal-bleeding subscore of 0 or 1. In ACT 2, 64 percent of patients who received 5 mg of infliximab and 69 percent of those who received 10 mg had a clinical response at week 8, as compared with 29 percent of those who received placebo (P<0.001 for both comparisons with placebo). In both studies, patients who received infliximab were more likely to have a clinical response at week 30 (P< or =0.002 for all comparisons). In ACT 1, more patients who received 5 mg or 10 mg of infliximab had a clinical response at week 54 (45 percent and 44 percent, respectively) than did those who received placebo (20 percent, P<0.001 for both comparisons). CONCLUSIONS: Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo. (ClinicalTrials.gov numbers, NCT00036439 and NCT00096655.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Self-citationTargan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Self-citationCoated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis
Schroeder, K. W., Tremaine, W. J., & Ilstrup, D. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198712243172603 · Cited by 3,026
Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
Present, D. H., Rutgeerts, P., Targan, S., Hanauer, S. B., Mayer, L., van Hogezand, R. A., Podolsky, D. K., Sands, B. E., Braakman, T., DeWoody, K. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905063401804 · Cited by 2,752
Self-citationInfliximab Maintenance Therapy for Fistulizing Crohn's Disease
Sands, B. E., Anderson, F. H., Bernstein, C. N., Chey, W. Y., Feagan, B. G., Fedorak, R. N., Kamm, M. A., Korzenik, J. R., Lashner, B. A., Onken, J. E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030815 · Cited by 2,226
Self-citationCyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy
Lichtiger, S., Present, D. H., Kornbluth, A., Gelernt, I., Bauer, J., Galler, G., Michelassi, F., & Hanauer, S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406303302601 · Cited by 1,714
Self-citationSeverity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis
Rutter, M., Saunders, B., Wilkinson, K., Rumbles, S., Schofield, G., Kamm, M., Williams, C., Price, A., Talbot, I., & Forbes, A. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.11.010 · Cited by 1,255
Faubion, W. A., Loftus, E. V., Harmsen, W. S., Zinsmeister, A. R., & Sandborn, W. J. (2001) · Gastroenterology · doi:10.1053/gast.2001.26279 · Cited by 1,144
Self-citationJärnerot, G., Hertervig, E., Friis-Liby, I., Blomquist, L., Karlén, P., Grännö, C., Vilien, M., Ström, M., Danielsson, Å., Verbaan, H., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.003 · Cited by 1,089
Rutgeerts, P., D'Haens, G., Targan, S., Vasiliauskas, E., Hanauer, S. B., Present, D. H., Mayer, L., Van Hogezand, R. A., Braakman, T., DeWoody, K. L., et al. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70332-x · Cited by 1,080
Self-citationComparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease
Rutgeerts, P., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.11.014 · Cited by 943
Self-citationColombel, J.-F., Loftus, E. V., Tremaine, W. J., Egan, L. J., Harmsen, W. S., Schleck, C. D., Zinsmeister, A. R., & Sandborn, W. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.10.047 · Cited by 899
Self-citationConstruction and initial characterization of a mouse-human chimeric anti-TNF antibody
Knight, D. M., Trinh, H., Le, J., Siegel, S., Shealy, D., McDonough, M., Scallon, B., Moore, M. A., Vilcek, J., Daddona, P., et al. (1993) · Molecular Immunology · doi:10.1016/0161-5890(93)90106-l · Cited by 703
Tumour necrosis factor alpha in stool as a marker of intestinal inflammation
Braegger, C. P., Nicholls, S., Murch, S. H., MacDonald, T. T., & Stephens, S. (1992) · The Lancet · doi:10.1016/0140-6736(92)90999-j · Cited by 683
Hanauer, S. B., Wagner, C. L., Bala, M. V., Mayer, L., Travers, S., Diamond, R. H., Olson, A. D., Bao, W., & Rutgeerts, P. J. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00238-1 · Cited by 608
Self-citationPenna, C., Dozois, R., Tremaine, W., Sandborn, W., LaRusso, N., Schleck, C., & Ilstrup, D. (1996) · Gut · doi:10.1136/gut.38.2.234 · Cited by 561
Self-citationInfliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease
ten Hove, T. (2002) · Gut · doi:10.1136/gut.50.2.206 · Cited by 545
Murch, S. H., Braegger, C. P., Walker-Smith, J. A., & MacDonald, T. T. (1993) · Gut · doi:10.1136/gut.34.12.1705 · Cited by 520
Colorectal cancer risk and mortality in patients with ulcerative colitis
Langholz, E., Munkholm, P., Davidsen, M., & Binder, V. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)91163-x · Cited by 493
Murch, S. H., Lamkin, V. A., Savage, M. O., Walker-Smith, J. A., & MacDonald, T. T. (1991) · Gut · doi:10.1136/gut.32.8.913 · Cited by 482
Rutter, M. D., Saunders, B. P., Wilkinson, K. H., Rumbles, S., Schofield, G., Kamm, M. A., Williams, C. B., Price, A. B., Talbot, I. C., & Forbes, A. (2004) · Gut · doi:10.1136/gut.2003.038505 · Cited by 442
Infliximab in the Treatment of Severe, Steroid-Refractory Ulcerative Colitis: A Pilot Study
Sands, B. E., Tremaine, W. J., Sandborn, W. J., Rutgeerts, P. J., Hanauer, S. B., Mayer, L., Targan, S. R., & Podolsky, D. K. (2001) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200105000-00001 · Cited by 422
Self-citationOlsen, K. Ø., Juul, S., Berndtsson, I., Öresland, T., & Laurberg, S. (2002) · Gastroenterology · doi:10.1053/gast.2002.30345 · Cited by 375
Sands, B. E., Blank, M. A., Patel, K., & Van Deventer, S. J. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00414-8 · Cited by 359
Self-citationProbert, C. S. J., Hearing, S. D., Schreiber, S., Kühbacher, T., Ghosh, S., Arnott, I. D. R., & Forbes, A. (2003) · Gut · doi:10.1136/gut.52.7.998 · Cited by 355
Ljung, T., Karlén, P., Schmidt, D., Hellström, P. M., Lapidus, A., Janczewska, I., Sjöqvist, U., & Löfberg, R. (2004) · Gut · doi:10.1136/gut.2003.018515 · Cited by 313
Mizoguchi, E., Mizoguchi, A., Takedatsu, H., Cario, E., De Jong, Y. P., Ooi, C. J., Xavier, R. J., Terhorst, C., Podolsky, D. K., & Bhan, A. K. (2002) · Gastroenterology · doi:10.1053/gast.2002.30347 · Cited by 186
Comparative Tolerability of Treatments for Inflammatory Bowel Disease
Stein, R. B., & Hanauer, S. B. (2000) · Drug Safety · doi:10.2165/00002018-200023050-00006 · Cited by 167
Self-citationOver-expression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis
Melgar, S., Yeung, M. M., Bas, A., Forsberg, G., Suhr, O. B., Öberg, Å., Hammarström, S., Danielsson, Å., & Hammarström, M. (2003) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2003.02268.x · Cited by 160
Medical therapy for ulcerative colitis 2004
Hanauer, S. B. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.071 · Cited by 156
Self-citationAmasheh, S., Barmeyer, C., Koch, C. S., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.03.010 · Cited by 139
Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study
Ochsenkühn, T., Sackmann, M. F., & Göke, B. (2004) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200411000-00014 · Cited by 124
Leeb, S. N., Vogl, D., Gunckel, M., Kießling, S., Falk, W., Göke, M. N., Schölmerich, J., Gelbmann, C. M., & Rogler, G. (2003) · Gastroenterology · doi:10.1016/j.gastro.2003.07.004 · Cited by 110
Cited by
Ungaro, R., Mehandru, S., Allen, P. B., Peyrin-Biroulet, L., & Colombel, J.-F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32126-2 · Cited by 3,531
Self-citationVedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Feagan, B. G., Rutgeerts, P., Sands, B. E., Hanauer, S., Colombel, J.-F., Sandborn, W. J., Van Assche, G., Axler, J., Kim, H.-J., Danese, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215734 · Cited by 2,888
Self-citationLamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
A microbial symbiosis factor prevents intestinal inflammatory disease
Mazmanian, S. K., Round, J. L., & Kasper, D. L. (2008) · Nature · doi:10.1038/nature07008 · Cited by 2,340
Ordás, I., Eckmann, L., Talamini, M., Baumgart, D. C., & Sandborn, W. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60150-0 · Cited by 2,078
Self-citation
Metadata
- Authors
- Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., de Villiers, W. J. S., Present, D., Sands, B. E., & Colombel, J. F.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-12-08
- Volume
- 353
- Issue
- 23
- Pages
- 2462-2476
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2171297959
- Cited by
- 3,902
- References
- 33
- FWCI
- 77.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.